Zoledronic acid for neonatal subcutaneous fat necrosis

Jeremy A Di Bari1, Jennifer A Nead2, Scott J Schurman3

  • 1Resident, Family MedicineSt. Joseph's Hospital Health Center 301 Prospect Ave Syracuse New York 13203 USA.

Insights

Subcutaneous fat necrosis in infants causing severe hypercalcemia is a critical emergency. Treatment with prednisolone and zoledronic acid effectively normalized calcium levels without complications.

Area of Science:

  • Neonatal medicine
  • Pediatric endocrinology
  • Dermatology

Background:

  • Subcutaneous fat necrosis (SFN) in infants can lead to life-threatening hypercalcemia.
  • Pathophysiology involves increased intestinal calcium absorption and bone resorption.

Observation:

  • A case of infant SFN with severe hypercalcemia (serum calcium 15 mg/dL) was observed.
  • The infant was treated with prednisolone and low-dose zoledronic acid.

Findings:

  • Serum calcium levels promptly normalized after treatment.
  • No rebound hypocalcemia or need for redosing of zoledronic acid was observed.

Implications:

  • This treatment approach offers a potential strategy for managing hypercalcemia in SFN.
  • Early intervention may prevent severe complications associated with hypercalcemia in infants.